Literature DB >> 12211197

Therapy-related MDS and AML in acute promyelocytic leukemia.

Mette Klarskov Andersen, Jens Pedersen-Bjergaard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12211197     DOI： 10.1182/blood-2002-03-0962

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.

Authors:  Yasmin Abaza; Hagop Kantarjian; Guillermo Garcia-Manero; Elihu Estey; Gautam Borthakur; Elias Jabbour; Stefan Faderl; Susan O'Brien; William Wierda; Sherry Pierce; Mark Brandt; Deborah McCue; Rajyalakshmi Luthra; Keyur Patel; Steven Kornblau; Tapan Kadia; Naval Daver; Courtney DiNardo; Nitin Jain; Srdan Verstovsek; Alessandra Ferrajoli; Michael Andreeff; Marina Konopleva; Zeev Estrov; Maria Foudray; David McCue; Jorge Cortes; Farhad Ravandi
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

Review 2.  Curing all patients with acute promyelocytic leukemia: are we there yet?

Authors:  Muhamed Baljevic; Jae H Park; Eytan Stein; Dan Douer; Jessica K Altman; Martin S Tallman
Journal:  Hematol Oncol Clin North Am       Date:  2011-12       Impact factor: 3.722

3.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.

Authors:  Farhad Ravandi; Eli Estey; Dan Jones; Stefan Faderl; Susan O'Brien; Jackie Fiorentino; Sherry Pierce; Deborah Blamble; Zeev Estrov; William Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

4.  Effect of therapy-related acute myeloid leukemia on the outcome of patients with acute myeloid leukemia.

Authors:  Ana Espírito ESPíRITO Santo; Sérgio Chacim; Isabel Ferreira; Luís Leite; Claudia Moreira; Dulcineia Pereira; Margarida Dantas Dantas Brito; Marta Nunes; Nelson Domingues; Isabel Oliveira; Ilídia Moreira; Angelo Martins; Luísa Viterbo; José Mário Mariz; Rui Medeiros
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

5.  Therapy-related acute promyelocytic leukemia: further insights into the molecular basis of the disease and showing the way forward in therapy.

Authors:  Farhad Ravandi
Journal:  Leuk Lymphoma       Date:  2009-07

Review 6.  Acute promyelocytic leukemia: where did we start, where are we now, and the future.

Authors:  C C Coombs; M Tavakkoli; M S Tallman
Journal:  Blood Cancer J       Date:  2015-04-17       Impact factor: 11.037

Review 7.  Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.

Authors:  Derek McCulloch; Christina Brown; Harry Iland
Journal:  Onco Targets Ther       Date:  2017-03-14       Impact factor: 4.147

8.  Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group.

Authors:  Lionel Adès; Xavier Thomas; Agnes Guerci Bresler; Emmanuel Raffoux; Olivier Spertini; Norbert Vey; Tony Marchand; Christian Récher; Arnaud Pigneux; Stephane Girault; Eric Deconinck; Claude Gardin; Olivier Tournilhac; Jean Francois Lambert; Patrice Chevallier; Stephane de Botton; Julie Lejeune; Hervé Dombret; Sylvie Chevret; Pierre Fenaux
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.